about
Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genesHeart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children.Heart failure from heart muscle disease in childhood: a 5-10 year follow-up study in the UK and Ireland.Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era.Outcome of shared care for pediatric cardiac transplantation between two nations with different health care systems.Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation.Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.Acute rejection after paediatric heart transplantation: far less common and less severe.Impairment of heart rate recovery after peak exercise predicts poor outcome after pediatric heart transplantation.A longer waiting game: bridging children to heart transplant with the Berlin Heart EXCOR device--the United Kingdom experience.Right ventricular dysfunction in children supported with pulsatile ventricular assist devices.Pediatric heart transplantation for congenital and restrictive cardiomyopathy.Diagnosis of post-transplant coronary artery disease using contrast-enhanced coronary vessel wall imaging at 3.0 Tesla.A Dobutamine paradox: eosinophilic myocarditis in the explanted heart of a 9-year-old girl undergoing cardiac transplantation.The value of cardiac MRI versus echocardiography in the pre-operative assessment of patients with Duchenne muscular dystrophy.Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment.Comparison of Segmental Versus Longitudinal Intravascular Ultrasound Analysis for Pediatric Cardiac Allograft Vasculopathy.Inflammatory Cytokines, Endothelial Function, and Chronic Allograft Vasculopathy in Children: An Investigation of the Donor and Recipient Vasculature After Heart Transplantation.Predictors and Outcome of Extracorporeal Life Support After Pediatric Heart Transplantation.Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation.Endothelial Dysfunction and Cytomegalovirus Replication in Pediatric Heart TransplantationAdverse Family Social Circumstances and Outcome in Pediatric Cardiac Transplant Recipients at a UK CenterCentral aortic stiffness, hypertension, and coronary allograft vasculopathy in children.New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and IrelandPeak oxygen uptake correlates with survival without clinical deterioration in ambulatory children with dilated cardiomyopathyThe importance of qualitative and quantitative regional wall motion abnormality assessment at rest in pediatric coronary allograft vasculopathyPotential for and timing of recovery in children with dilated cardiomyopathyMelody valve in aortic position to facilitate mechanical circulatory support as a bridge to cardiac transplantationComparative Study of Pediatric Coronary Allograft Vasculopathy Between Single Centers in North America and United KingdomPermanent pacemaker implantation after pediatric heart transplantation: Risk factors, indications, and outcomes
P50
Q28279508-217F8FD3-A316-4ED6-9ED3-5D302D066778Q35771912-F21B09E7-43CF-4432-8A92-D963B78BE911Q37344141-56D8EB5F-516E-4804-B618-D02BF9D580F6Q37523710-E732FBC0-3574-4E93-B590-DB60B37E4B3AQ38363287-729536E2-5AED-4604-A5EF-436CDE7BC64BQ38615407-C191A9FC-A3A1-45EF-9121-8E013B3F7376Q38808221-45907058-D1EF-4971-B44E-5AB43A8D8EACQ42165651-DA3023A4-6F68-4130-8578-589595156773Q43290778-8C6E106C-70BC-4529-811A-6C7ACADADC7CQ44419728-7DC2CE74-0206-4760-B301-F24F82C3A933Q44790062-EFEE995B-E093-4ADC-845F-52E3EB61FEB4Q44922762-3D4D1102-6C16-46DD-BD42-23B08B64266AQ45757062-1C86FD25-BEAC-474E-A9E5-28000F859EAFQ46436102-7215D598-E0B2-4DB2-BAF7-5F2899768A25Q46704992-D3706337-44B4-4C01-B5C7-FD4BBDBE0476Q47725466-FEF6E4D0-8CF0-461A-85E9-FA46BFF8ED6EQ48187611-4429A1CD-3F6C-4AC5-88E4-77FC2969A091Q50037020-1DED0207-7510-4C28-83A5-FBA893BFAF3CQ53261832-86AE7C40-1CCA-4CD6-9C51-6743274E9425Q53527108-E4D0C3FA-7342-463D-83E3-117D44847EFDQ54261476-60F78F63-0534-4311-B34B-BA976BCAA1C8Q60458196-BA8708E5-2130-4396-A113-937933F15C3AQ63234731-43145829-7C30-4834-9E5F-940DFC2A76BFQ64980241-723036DB-1CA1-48B2-90ED-8658160F25DFQ80217120-B78E5B12-0784-4C8A-92A0-7AD7EA10DBC7Q84985924-B33A8BA6-FE25-4B3F-97DD-33EF78915286Q88589178-53362633-2524-453A-AB7B-89D6A96EB605Q89055435-1F2EAD18-88A1-4D0E-9DA4-10E92844B435Q90377424-3898CC4B-FD3F-4AD0-A3B8-4C0DEAA4F721Q90705034-5B647220-EED3-45A8-8BEB-1C0CDAFA76E1Q91798536-DC505F58-C38D-47D1-BED9-351075FE4FFB
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Matthew J Fenton
@en
Matthew J Fenton
@nl
type
label
Matthew J Fenton
@en
Matthew J Fenton
@nl
prefLabel
Matthew J Fenton
@en
Matthew J Fenton
@nl
P31
P496
0000-0001-9757-7954